{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:25:21Z","timestamp":1786998321978,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ygyno.2023.12.021","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T16:45:16Z","timestamp":1704300316000},"page":"155-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125"],"prefix":"10.1016","volume":"181","author":[{"given":"Amal","family":"AlSomairi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samah","family":"Himayda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Altelmesani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Yun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2023.12.021_bb0005","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/IJWH.S197604","article-title":"Ovarian cancer in the world: epidemiology and risk factors","volume":"11","author":"Momenimovahed","year":"2019","journal-title":"Int. J. Women\u2019s Health"},{"issue":"6","key":"10.1016\/j.ygyno.2023.12.021_bb0010","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.ygyno.2023.12.021_bb0015","first-page":"209","article-title":"Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"2","key":"10.1016\/j.ygyno.2023.12.021_bb0020","doi-asserted-by":"crossref","first-page":"431","DOI":"10.4143\/crt.2019.139","article-title":"Prediction of Cancer incidence and mortality in Korea, 2019","volume":"51","author":"Jung","year":"2019","journal-title":"Cancer Res. Treat."},{"key":"10.1016\/j.ygyno.2023.12.021_bb0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.639839","article-title":"Conditional relative survival of ovarian Cancer: a Korean National Cancer Registry Study","volume":"11","author":"Shin","year":"2021","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2023.12.021_bb0030","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.hoc.2018.07.002","article-title":"Risk factors for ovarian carcinoma","volume":"32","author":"Mallen","year":"2018","journal-title":"Hematol. Oncol. Clin. North Am."},{"issue":"1","key":"10.1016\/j.ygyno.2023.12.021_bb0035","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ijc.32075","article-title":"Ovarian cancer risk factors by tumor aggressiveness: an analysis from the ovarian Cancer cohort consortium","volume":"145","author":"Fortner","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2023.12.021_bb0040","series-title":"Preventive Oncology for the Gynecologist","first-page":"223","article-title":"Epidemiology and risk factors for ovarian Cancer","author":"Singla","year":"2019"},{"issue":"2 Pt 1","key":"10.1016\/j.ygyno.2023.12.021_bb0045","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/AOG.0b013e318224fce2","article-title":"Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass","volume":"118","author":"Moore","year":"2011","journal-title":"Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.ygyno.2023.12.021_bb0050","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1007\/s00330-021-08305-x","article-title":"Evaluation of patients with advanced epithelial ovarian cancer before primary treatment: correlation between tumour burden assessed by [(18)F]FDG PET\/CT volumetric parameters and tumour markers HE4 and CA125","volume":"32","author":"Glickman","year":"2022","journal-title":"Eur. Radiol."},{"issue":"9","key":"10.1016\/j.ygyno.2023.12.021_bb0055","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/14737140.2017.1360138","article-title":"The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review","volume":"17","author":"Scaletta","year":"2017","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"2","key":"10.1016\/j.ygyno.2023.12.021_bb0060","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317691189","article-title":"Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer","volume":"39","author":"Vallius","year":"2017","journal-title":"Tumour Biol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.12.021_bb0065","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ygyno.2008.10.010","article-title":"A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma","volume":"112","author":"Chi","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.12.021_bb0070","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2008.09.020","article-title":"Can the preoperative ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study","volume":"112","author":"Vorgias","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2023.12.021_bb0075","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3802\/jgo.2013.24.2.141","article-title":"CA-125 cut-off value as a predictor for complete interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer","volume":"24","author":"Furukawa","year":"2013","journal-title":"J. Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2023.12.021_bb0080","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ygyno.2012.11.040","article-title":"Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?","volume":"128","author":"Angioli","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2023.12.021_bb0085","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/14737140.2017.1360138","article-title":"The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review","volume":"17","author":"Scaletta","year":"2017","journal-title":"Expert. Rev. Anticancer. Ther."},{"issue":"12","key":"10.1016\/j.ygyno.2023.12.021_bb0090","doi-asserted-by":"crossref","first-page":"12389","DOI":"10.1007\/s13277-014-2553-1","article-title":"Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer","volume":"35","author":"Vallius","year":"2014","journal-title":"Tumour Biol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.12.021_bb0095","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14010098","article-title":"The increasing prognostic and predictive roles of the tumor primary Chemosensitivity assessed by CA-125 elimination rate constant K (KELIM) in ovarian Cancer: anarrative review","volume":"14","author":"Lauby","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"11","key":"10.1016\/j.ygyno.2023.12.021_bb0100","doi-asserted-by":"crossref","first-page":"14765","DOI":"10.1007\/s13277-016-5335-0","article-title":"Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer","volume":"37","author":"Shen","year":"2016","journal-title":"Tumour Biol."},{"issue":"4","key":"10.1016\/j.ygyno.2023.12.021_bb0105","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/IGC.0000000000000944","article-title":"The role of HE4, a novel biomarker, in predicting optimal Cytoreduction after neoadjuvant chemotherapy in advanced ovarian Cancer","volume":"27","author":"Plotti","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2023.12.021_bb0110","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13048-021-00845-6","article-title":"Kinetics of HE4 and CA125 as prognosis biomarkers during neoadjuvant chemotherapy in advanced epithelial ovarian cancer","volume":"14","author":"Alegr\u00eda-Ba\u00f1os","year":"2021","journal-title":"J. Ovarian Res."},{"issue":"7","key":"10.1016\/j.ygyno.2023.12.021_bb0115","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/aogs.13814","article-title":"CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer","volume":"99","author":"Kessous","year":"2020","journal-title":"Acta Obstet. Gynecol. Scand."},{"issue":"12","key":"10.1016\/j.ygyno.2023.12.021_bb0120","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1245\/s10434-013-3091-6","article-title":"Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy","volume":"20","author":"Petrillo","year":"2013","journal-title":"Ann. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2023.12.021_bb0125","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/IGC.0000000000000843","article-title":"Patterns of recurrence and clinical outcome of patients with stage IIIC to stage IV epithelial ovarian Cancer in complete response after primary Debulking surgery plus chemotherapy or neoadjuvant chemotherapy followed by interval Debulking surgery: an Ita","volume":"27","author":"Gadducci","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2023.12.021_bb0130","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s13048-021-00908-8","article-title":"The prognostic factor for recurrence in advanced-stage high-grade serous ovarian cancer after complete clinical remission: a nested case-control study","volume":"14","author":"Wang","year":"2021","journal-title":"J. Ovarian Res."},{"issue":"4","key":"10.1016\/j.ygyno.2023.12.021_bb0135","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/14737159.2018.1457436","article-title":"Prognostic value of serum and tissue HE4 expression in ovarian cancer: a systematic review with meta-analysis of 90 studies","volume":"18","author":"Cao","year":"2018","journal-title":"Expert. Rev. Mol. Diagn."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582301627X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582301627X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T04:07:25Z","timestamp":1758773245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582301627X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":27,"alternative-id":["S009082582301627X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.12.021","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2023.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}